FULC Fulcrum Therapeutics, Inc.

Nasdaq fulcrumtx.com


$ 9.43 $ 0.66 (7.54 %)    

Wednesday, 15-Oct-2025 14:06:35 EDT
QQQ $ 601.21 $ -2.67 (-0.44 %)
DIA $ 463.13 $ -1.51 (-0.32 %)
SPY $ 664.01 $ -2.79 (-0.42 %)
TLT $ 90.53 $ -0.43 (-0.47 %)
GLD $ 386.87 $ 0.91 (0.24 %)
$ 8.69
$ 8.75
$ 9.38 x 159
$ 9.43 x 34
$ 8.74 - $ 9.41
$ 2.32 - $ 9.88
537,667
na
470.06M
$ 1.77
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-29-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 11-13-2024 09-30-2024 10-Q
5 07-31-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 11-07-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 03-09-2023 12-31-2022 10-K
12 11-08-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-03-2022 12-31-2021 10-K
16 11-04-2021 09-30-2021 10-Q
17 08-10-2021 06-30-2021 10-Q
18 05-06-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 11-10-2020 09-30-2020 10-Q
21 08-11-2020 06-30-2020 10-Q
22 05-13-2020 03-31-2020 10-Q
23 03-05-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-26-2019 06-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fulcrum-therapeutics-to-present-preclinical-data-on-ftx-6274-for-advanced-prostate-cancer-at-esmo-2025

Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small mol...

Core News & Articles

Gainers Galecto (NASDAQ: GLTO) stock rose 21.6% to $5.41 during Thursday's after-market session. The market value of their...

 rbc-capital-maintains-sector-perform-on-fulcrum-therapeutics-raises-price-target-to-5

RBC Capital analyst Luca Issi maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Sector Perform and raises the price target...

 hc-wainwright--co-upgrades-fulcrum-therapeutics-to-buy-raises-price-target-to-12

HC Wainwright & Co. analyst Andrew Fein upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Buy and raises the p...

 fulcrum-therapeutics-reports-results-from-12-mg-dose-cohort-of-phase-1b-pioneer-trial-of-pociredir-in-sickle-cell-disease

― Robust and clinically meaningful absolute mean fetal hemoglobin (HbF) induction of 8.6% from baseline at 12 weeks of treatmen...

 fulcrum-therapeutics-to-present-topline-results-from-12-mg-dose-cohort-of-phase-1b-pioneer-trial-of-pociredir-in-sickle-cell-disease

Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small mol...

 piper-sandler-maintains-overweight-on-fulcrum-therapeutics-raises-price-target-to-9

Piper Sandler analyst Edward Tenthoff maintains Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight and raises the price ta...

 leerink-partners-upgrades-fulcrum-therapeutics-to-outperform-raises-price-target-to-12

Leerink Partners analyst Joseph Schwartz upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Market Perform to Outperform and r...

 cantor-fitzgerald-upgrades-fulcrum-therapeutics-to-overweight-announces-10-price-target

Cantor Fitzgerald analyst Kristen Kluska upgrades Fulcrum Therapeutics (NASDAQ:FULC) from Neutral to Overweight and announce...

 fulcrum-therapeutics-expects-current-cash-runway-be-sufficient-to-fund-operating-requirements-into-at-least-2027

Cash Runway GuidanceBased on its current operating plans, Fulcrum continues to expect that its current cash, cash equivalents, ...

 fulcrum-therapeutics-q1-eps-028-beats-030-estimate-cash-and-equivalents-2266m

Fulcrum Therapeutics (NASDAQ:FULC) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of ...

 bristol-myers-acquired-myokardia-drops-fulcrum-agreement-ending-cardiomyopathy-research-deal

MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION